Agenus ($AGEN) Rose 54% After $340M Private Placement — Scored 85/100 at 6:00 AM ET
AGEN stock rose 54% after announcing an oversubscribed $340M private placement. RTPR scored the release 85/100 at 6:00 AM ET.
Agenus (NASDAQ: AGEN) stock is up today after the company announced an oversubscribed private placement of up to $340 million, rising as much as 54% from its price when the release crossed the wire. RTPR assigned the release an impact score of 85/100 at 6:00 AM ET, when the stock traded at $3.57.
What the release announced
According to the press release (free account required), Agenus raised $85 million upfront plus up to $255 million in potential warrant exercises. The funds will advance the company's Phase 3 ROBBIN trial evaluating its BOT+BAL combination as a neoadjuvant treatment for microsatellite stable (MSS) colon cancer.
The placement was oversubscribed, and the total potential proceeds of $340 million include the full exercise of warrants issued in the deal.
What the stock did
Following the announcement, AGEN traded from $3.57 to a session high of $5.50, a gain of about 54%.
Historical context
This release received an impact score of 85/100.
- Releases scoring 80-100 produced a 15%+ move 50% of the time.
- Sample size: 112 settled outcomes over the past 90 days.
- Historical observations only, not predictions. Full band-by-band table on the impact scoreboard.
Timeline
- 6:00:00 AM ET — press release crossed the wire
- +16 ms — RTPR delivered the release
- 6:00:24 AM ET — impact score written: 85/100
- $3.57 — price at publication
- $5.50 — intraday high (54% above the price at publication)
Real-time impact scores on every press release are part of RTPR Pro. Impact scores are in beta; historical tendencies, not predictions or investment advice.